Randomized Phase 2 Study of Trebananib (AMG 386) with or without Continued Anti-Vascular Endothelial Growth Factor Therapy in Patients with Renal Cell Carcinoma Who Have Progressed on Bevacizumab, Pazopanib, Sorafenib, or Sunitinib – Results of NCI/CTEP Protocol 9048

Thomas J. Semrad,Susan Groshen,Chunqiao Luo,Sumanta K. Pal,Ulka N. Vaishampayan,Monika Joshi,David I. Quinn,Philip C. Mack,David R. Gandara,Primo N. Lara

Randomized Phase 2 Study of Trebananib (AMG 386) with or without Continued Anti-Vascular Endothelial Growth Factor Therapy in Patients with Renal Cell Carcinoma Who Have Progressed on Bevacizumab, Pazopanib, Sorafenib, or Sunitinib – Results of NCI/CTEP Protocol 9048

2019

Thomas J. Semrad
Susan Groshen
Chunqiao Luo
Sumanta K. Pal
Ulka N. Vaishampayan
Monika Joshi
David I. Quinn
Philip C. Mack
David R. Gandara
Primo N. Lara

Background: In renal cell carcinoma (RCC), angiopoietin (Ang) 2 is elevated at the time of progression on anti-vascular endothelial growth factor (VEGF) therapy and may contribute to resistance.

Keywords:

Bevacizumab
Pazopanib
Phases of clinical research
Anti–vascular endothelial growth factor therapy
Oncology
Renal cell carcinoma
Sorafenib
Trebananib
Sunitinib
Internal medicine
Medicine
Progression-free survival
Interim analysis

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations